These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33422377)

  • 1. Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity.
    Caldera F; Mercer M; Samson SI; Pitt JM; Hayney MS
    Vaccine; 2021 Mar; 39 Suppl 1():A15-A23. PubMed ID: 33422377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
    Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ
    Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis.
    Samson SI; Leventhal PS; Salamand C; Meng Y; Seet BT; Landolfi V; Greenberg D; Hollingsworth R
    Expert Rev Vaccines; 2019 Mar; 18(3):295-308. PubMed ID: 30689467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients.
    Chong PP; Handler L; Weber DJ
    Clin Infect Dis; 2018 May; 66(11):1802-1811. PubMed ID: 29253095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza vaccination in immunocompromised patients: efficacy and safety.
    Zbinden D; Manuel O
    Immunotherapy; 2014; 6(2):131-9. PubMed ID: 24491087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
    Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK
    JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Wateska A; France GS; Zimmerman RK
    Vaccine; 2017 Oct; 35(42):5708-5713. PubMed ID: 28890196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study.
    Hu Y; Chu K; Lavis N; Li X; Liang B; Liu S; Shao M; Shu JD; Tabar C; Samson S
    Hum Vaccin Immunother; 2019; 15(5):1066-1069. PubMed ID: 30779689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience.
    Nicolay U; Heijnen E; Nacci P; Patriarca PA; Leav B
    Int J Infect Dis; 2019 Aug; 85S():S1-S9. PubMed ID: 30926542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination.
    Morelon E; Pouteil Noble C; Daoud S; Cahen R; Goujon-Henry C; Weber F; Laurent PE; Kaiserlian D; Nicolas JF
    Vaccine; 2010 Oct; 28(42):6885-90. PubMed ID: 20709000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluzone® High-Dose Influenza Vaccine.
    Robertson CA; DiazGranados CA; Decker MD; Chit A; Mercer M; Greenberg DP
    Expert Rev Vaccines; 2016 Dec; 15(12):1495-1505. PubMed ID: 27813430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
    DiazGranados CA; Dunning AJ; Kimmel M; Kirby D; Treanor J; Collins A; Pollak R; Christoff J; Earl J; Landolfi V; Martin E; Gurunathan S; Nathan R; Greenberg DP; Tornieporth NG; Decker MD; Talbot HK
    N Engl J Med; 2014 Aug; 371(7):635-45. PubMed ID: 25119609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Booster and higher antigen doses of inactivated influenza vaccine in HIV-infected patients.
    Johnston JA; Tincher LB; Lowe DK
    Ann Pharmacother; 2013 Dec; 47(12):1712-6. PubMed ID: 24259616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications.
    Patel SS; Bizjajeva S; Heijnen E; Oberye J
    Int J Infect Dis; 2019 Aug; 85S():S18-S25. PubMed ID: 31051279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
    Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
    Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seasonal influenza vaccine in immunocompromised persons.
    Bosaeed M; Kumar D
    Hum Vaccin Immunother; 2018 Jun; 14(6):1311-1322. PubMed ID: 29485353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women.
    Munoz FM; Jackson LA; Swamy GK; Edwards KM; Frey SE; Stephens I; Ault K; Winokur P; Petrie CR; Wolff M; Patel SM; Keitel WA
    Vaccine; 2018 Dec; 36(52):8054-8061. PubMed ID: 30416018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.